Apr 03, 2020 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Apr 03, 2020 - J&J (JNJ) to begin human clinical studies on coronavirus vaccine candidate in September. Sanofi (SNY) begins outside U.S. study on Kevzara for severe COVID-19 infection.
Apr 06, 2020 - Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Apr 06, 2020 - Novo Nordisk (NVO) gains the EU approval for Rybelsus to address adult patients with insufficiently-controlled type II diabetes for improving glycemic control as an adjunct to diet and exercise.
Apr 09, 2020 - Pfizer (PFE) secures an FDA approval for Braftovi combined with Lilly's Erbitux to treat BRAFV600E-mutant metastatic colorectal cancer in patients who received prior therapy.
Apr 13, 2020 - Lilly (LLY) plans to develop its RA drug, Olumiant, as well as a pipeline candidate as potential treatments for COVID-19. Clinical studies are expected to begin this month.
Apr 15, 2020 - Despite the economic disaster, a few stocks are likely to report better-than expected earnings results when they report their financial numbers this month.
Apr 15, 2020 - AstraZeneca (AZN) to initiate enrollment in a clinical study to evaluate its blood cancer drug, Calquence, as a potential treatment for patients hospitalized with COVID-19 infection.
Apr 16, 2020 - Vanda (VNDA) and The Feinstein Institutes for Medical Research initiate enrollment in the phase III ODYSSEY study on tradipitant to treat inflammatory lung injury associated with COVID-19 infection.
Apr 17, 2020 - Is (LLY) Outperforming Other Medical Stocks This Year?